Sense Biodetection on Wednesday announced it has signed an agreement with Biotecom for the nonexclusive distribution of Sense’s Veros instrument-free molecular testing platform in Chile.
“This agreement is significant for Sense as it marks our entry into the South American market,” Ryan Roberts, Sense's chief commercial officer, said in a statement.
“Together with Biotecom, we believe that by adding the instrument-free Veros COVID-19 to their portfolio, healthcare providers in Chile will be able to provide faster diagnosis and exceptional care for their patients right at the point of use by taking advantage of this rapid, laboratory-quality molecular test,” Roberts added.
Sense previously signed a distribution agreement with Abacus dx, allowing Abacus to distribute the Veros platform in Australia and New Zealand.
The Veros system uses rapid molecular amplification technology to provide rapid, highly accurate, point-of-care testing, Sense said. It is an instrument-free, single-use COVID-19 product that produces polymerase chain reaction (PCR)-quality results within 15 minutes, Sense also said.
Veros can detect all Variants of Interest and Concern as identified by the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), including Omicron and its subvariants, the company added.
